文献速递肝病胰腺与胆道疾病消化道肿瘤与早癌

CA19-9纵向分析揭示原发性硬化性胆管炎患者胆道癌发生前的个体化正常范围与早期变化

Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-27

本研究回顾性分析247例原发性硬化性胆管炎患者共1818次CA19-9检测值,其中32例发生胆道恶性肿瘤。无癌患者CA19-9中位数为15.6 U/mL,个体指数为0.37,参考变化值为46.23%。胆道癌患者确诊前3个月CA19-9显著高于确诊前6个月及无癌患者末次随访前3个月,92.9%的胆道癌患者在确诊前一年内CA19-9升高超过46.23%。

要点

  • 原发性硬化性胆管炎患者CA19-9高度个体化,参考变化值应优先于参考区间。
  • 无癌患者CA19-9在初诊后1至20年随访中无显著变化。
  • 胆道癌患者确诊前3个月CA19-9已出现升高,确诊前一年内升幅常超过46.23%。

核心结论

  • 原发性硬化性胆管炎患者CA19-9高度个体化,参考变化值应优先于参考区间。
  • 本研究中无癌患者CA19-9保持稳定,而发生胆道癌者早期即出现升高。
  • 定期检测CA19-9可能改善此类恶性肿瘤的早期发现。

研究设计与样本

  • 回顾性分析原发性硬化性胆管炎伴或不伴胆道恶性肿瘤患者的CA19-9值,共获得247例患者的1818个CA19-9值,其中32例伴恶性肿瘤。
  • 在无癌患者中计算个体指数和参考变化值,并进行CA19-9长期分析,评估癌症诊断前CA19-9的变化。

主要发现

  • 无癌个体CA19-9中位数为15.6 U/mL,个体指数为0.37,参考变化值为46.23%。
  • 无癌患者初诊原发性硬化性胆管炎后1、2、5、7、10、15和20年CA19-9无显著变化。
  • 胆道癌患者确诊前3个月CA19-9高于确诊前6个月(P < 0.05),也高于无癌患者末次随访前3个月(P < 0.05)。
  • 92.9%的胆道癌患者在癌症确诊前一年内CA19-9升高超过46.23%。

关键数值与推荐

  • 无癌个体CA19-9中位数为15.6 U/mL。
  • 个体指数为0.37,参考变化值为46.23%。
  • 胆道癌患者确诊前3个月CA19-9较确诊前6个月及无癌患者末次随访前3个月升高(P < 0.05)。
  • 92.9%的胆道癌患者确诊前一年内CA19-9升幅超过46.23%。

临床怎么用

  • 作者认为,原发性硬化性胆管炎患者CA19-9高度个体化,参考变化值应优先于参考区间。
  • 作者认为,定期检测CA19-9可能改善胆道癌的早期发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary sclerosing cholangitis is associated with an increased risk of biliary tract cancer. Carbohydrate antigen 19-9 (CA19-9) can be used to screen for these malignancies. AIM: To perform a longitudinal analysis of CA19-9 in patients with primary sclerosing cholangitis. METHODS: We conducted a retrospective analysis of CA19-9 values in patients who had primary sclerosing cholangitis, with and without biliary malignancy. We calculated the index of individuality and reference change value in patients who were cancer-free. Long-term analysis of CA19-9 in cancer-free patients was performed and we assessed the change of CA19-9 prior to diagnosis of cancer. RESULTS: We obtained 1818 CA19-9 values from 247 patients, including 32 with malignancy. Median CA19-9 in cancer-free individuals was 15.6 U/mL. The index of individuality was 0.37 and the reference change value was 46.23%. In cancer-free patients, no significant change in CA19-9 was observed at 1, 2, 5, 7, 10, 15, and 20 years after initial diagnosis of primary sclerosing cholangitis. In patients with biliary tract cancer, CA19-9 was higher at 3 months prior to diagnosis (P < 0.05) than at 6 months before diagnosis and was also higher than at 3 months prior to last follow-up in cancer-free patients (P < 0.05). In 92.9% of patients with biliary cancer, we found an increase in CA19-9 of >46.23% in the year prior to cancer diagnosis. CONCLUSIONS: CA19-9 in patients with primary sclerosing cholangitis is highly individual, and the reference change value should be preferred to reference intervals. In this study, CA19-9 remained stable in patients who were cancer-free but increased early in those who developed biliary tract cancer. Regular CA19-9 measurement might improve early detection of these malignancies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wannhoff A, Brune M, Knierim J, et al. Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2019. PMID: 30687954. doi:10.1111/apt.15146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。